Published in Biochemistry on November 14, 1995
Inhibition of transcription by platinum antitumor compounds. Metallomics (2009) 1.88
New clues for platinum antitumor chemistry: kinetically controlled metal binding to DNA. Proc Natl Acad Sci U S A (2003) 1.51
Cisplatin inhibits synthesis of ribosomal RNA in vivo. Nucleic Acids Res (1998) 1.49
Phenanthriplatin, a monofunctional DNA-binding platinum anticancer drug candidate with unusual potency and cellular activity profile. Proc Natl Acad Sci U S A (2012) 1.48
Steroid hormones induce HMG1 overexpression and sensitize breast cancer cells to cisplatin and carboplatin. Proc Natl Acad Sci U S A (2000) 1.46
Transcription-coupled and DNA damage-dependent ubiquitination of RNA polymerase II in vitro. Proc Natl Acad Sci U S A (2002) 1.45
X-ray structure and mechanism of RNA polymerase II stalled at an antineoplastic monofunctional platinum-DNA adduct. Proc Natl Acad Sci U S A (2010) 1.39
Dial 9-1-1 for p53: mechanisms of p53 activation by cellular stress. Neoplasia (2000) 1.36
Persistent DNA damage inhibits S-phase and G2 progression, and results in apoptosis. Mol Biol Cell (1997) 1.31
Cisplatin induces a mitochondrial-ROS response that contributes to cytotoxicity depending on mitochondrial redox status and bioenergetic functions. PLoS One (2013) 1.14
Redox state-dependent interaction of HMGB1 and cisplatin-modified DNA. Biochemistry (2011) 1.13
Transcription inhibition by platinum-DNA cross-links in live mammalian cells. J Am Chem Soc (2010) 1.05
Role of glutathione S-transferase P1-1 in the cellular detoxification of cisplatin. Mol Cancer Ther (2008) 0.92
Monofunctional platinum-DNA adducts are strong inhibitors of transcription and substrates for nucleotide excision repair in live mammalian cells. Cancer Res (2011) 0.91
Preparation of mammalian expression vectors incorporating site-specifically platinated-DNA lesions. Bioconjug Chem (2009) 0.91
Role of endonucleases XPF and XPG in nucleotide excision repair of platinated DNA and cisplatin/oxaliplatin cytotoxicity. Chembiochem (2011) 0.88
Molecular basis of transcriptional fidelity and DNA lesion-induced transcriptional mutagenesis. DNA Repair (Amst) (2014) 0.85
Comparison of the nucleic acid covalent binding capacity of two nitro-substituted benzazolo[3,2-a]quinolinium salts upon enzymatic reduction. Toxicol In Vitro (2007) 0.83
Loss of DNA mismatch repair facilitates reactivation of a reporter plasmid damaged by cisplatin. Br J Cancer (1999) 0.82
RNA polymerase II transcriptional fidelity control and its functional interplay with DNA modifications. Crit Rev Biochem Mol Biol (2015) 0.80
Rearrangement of interstrand cross-links into intrastrand cross-links in cis-diamminedichloroplatinum(II)-modified DNA. Nucleic Acids Res (1997) 0.79
Cisplatin and ultra-violet-C synergistically down-regulate receptor tyrosine kinases in human colorectal cancer cells. Mol Cancer (2012) 0.79
The anti-tumour agent, cisplatin, and its clinically ineffective isomer, transplatin, produce unique gene expression profiles in human cells. Cancer Inform (2008) 0.75
A density functional reactivity theory (DFRT) based approach to understand the interaction of cisplatin analogues with protecting agents. J Comput Aided Mol Des (2014) 0.75
Structure, Recognition, and Processing of Cisplatin-DNA Adducts. Chem Rev (1999) 5.63
In vivo mutagenesis by O6-methylguanine built into a unique site in a viral genome. Proc Natl Acad Sci U S A (1984) 4.09
Mechanistic studies of ionizing radiation and oxidative mutagenesis: genetic effects of a single 8-hydroxyguanine (7-hydro-8-oxoguanine) residue inserted at a unique site in a viral genome. Biochemistry (1990) 3.94
Crystal structure of a bacterial non-haem iron hydroxylase that catalyses the biological oxidation of methane. Nature (1993) 3.90
Crystal structure of double-stranded DNA containing the major adduct of the anticancer drug cisplatin. Nature (1995) 3.67
Mechanisms of resistance to cisplatin. Mutat Res (2001) 3.51
Lethal mutagenesis of HIV with mutagenic nucleoside analogs. Proc Natl Acad Sci U S A (1999) 2.85
Specific binding of chromosomal protein HMG1 to DNA damaged by the anticancer drug cisplatin. Science (1992) 2.79
Repair of an interstrand DNA cross-link initiated by ERCC1-XPF repair/recombination nuclease. J Biol Chem (2000) 2.60
Structural identification of the major DNA adduct formed by aflatoxin B1 in vitro. Proc Natl Acad Sci U S A (1977) 2.53
Cisplatin and DNA repair in cancer chemotherapy. Trends Biochem Sci (1995) 2.36
Basis for recognition of cisplatin-modified DNA by high-mobility-group proteins. Nature (1999) 2.35
X-ray structure of a DNA decamer containing 7,8-dihydro-8-oxoguanine. Proc Natl Acad Sci U S A (1995) 2.30
Repair of cisplatin--DNA adducts by the mammalian excision nuclease. Biochemistry (1996) 2.17
Fluorescent sensors for Zn(2+) based on a fluorescein platform: synthesis, properties and intracellular distribution. J Am Chem Soc (2001) 2.15
Analysis of incision sites produced by human cell extracts and purified proteins during nucleotide excision repair of a 1,3-intrastrand d(GpTpG)-cisplatin adduct. J Biol Chem (1996) 2.13
HMG-domain proteins specifically inhibit the repair of the major DNA adduct of the anticancer drug cisplatin by human excision nuclease. Proc Natl Acad Sci U S A (1994) 2.12
Isolation and characterization of human cDNA clones encoding a high mobility group box protein that recognizes structural distortions to DNA caused by binding of the anticancer agent cisplatin. Proc Natl Acad Sci U S A (1992) 2.04
High-mobility-group 1 protein mediates DNA bending as determined by ring closures. Proc Natl Acad Sci U S A (1993) 2.03
Geometry of the soluble methane monooxygenase catalytic diiron center in two oxidation states. Chem Biol (1995) 1.95
Cisplatin: from DNA damage to cancer chemotherapy. Prog Nucleic Acid Res Mol Biol (2001) 1.95
Sequence-dependent termination of in vitro DNA synthesis by cis- and trans-diamminedichloroplatinum (II). Proc Natl Acad Sci U S A (1985) 1.95
Induction of reversible complexes between eukaryotic DNA topoisomerase I and DNA-containing oxidative base damages. 7, 8-dihydro-8-oxoguanine and 5-hydroxycytosine. J Biol Chem (1999) 1.91
Mutagenicity and repair of oxidative DNA damage: insights from studies using defined lesions. Mutat Res (1998) 1.88
Binding of the antitumor drug cis-diamminedichloroplatinum(II) (cisplatin) to DNA. Biochim Biophys Acta (1985) 1.85
Recognition of cisplatin adducts by cellular proteins. Mutat Res (2001) 1.78
Characterization of a mammalian homolog of the Escherichia coli MutY mismatch repair protein. Mol Cell Biol (1995) 1.75
High-throughput synthesis and screening of platinum drug candidates. J Biol Inorg Chem (2000) 1.75
Oxidized, deaminated cytosines are a source of C --> T transitions in vivo. Proc Natl Acad Sci U S A (1998) 1.75
2.4 A crystal structure of an oxaliplatin 1,2-d(GpG) intrastrand cross-link in a DNA dodecamer duplex. Inorg Chem (2001) 1.71
Binding of cis- and trans-dichlorodiammineplatinum(II) to DNA: evidence for unwinding and shortening of the double helix. Science (1979) 1.70
Crystal structures of the methane monooxygenase hydroxylase from Methylococcus capsulatus (Bath): implications for substrate gating and component interactions. Proteins (1997) 1.68
DNA unwinding produced by site-specific intrastrand cross-links of the antitumor drug cis-diamminedichloroplatinum(II). Biochemistry (1991) 1.68
Identification of the principal aflatoxin B1-DNA adduct formed in vivo in rat liver. Proc Natl Acad Sci U S A (1978) 1.64
The major adduct of the antitumor drug cis-diamminedichloroplatinum(II) with DNA bends the duplex by approximately equal to 40 degrees toward the major groove. Proc Natl Acad Sci U S A (1988) 1.61
X-ray structure of the major adduct of the anticancer drug cisplatin with DNA: cis-[Pt(NH3)2(d(pGpG))]. Science (1985) 1.57
Mononuclear and Polynuclear Chemistry of Rhenium (III): Its Pronounced Homophilicity. Science (1964) 1.56
Genetic effects of oxidative DNA damage: comparative mutagenesis of 7,8-dihydro-8-oxoguanine and 7,8-dihydro-8-oxoadenine in Escherichia coli. Nucleic Acids Res (1992) 1.55
Ixr1, a yeast protein that binds to platinated DNA and confers sensitivity to cisplatin. Science (1993) 1.54
Site-specifically modified oligodeoxynucleotides as probes for the structural and biological effects of DNA-damaging agents. Chem Res Toxicol (1992) 1.53
The chemistry and biology of aflatoxin B(1): from mutational spectrometry to carcinogenesis. Carcinogenesis (2001) 1.50
Crystal structures of the soluble methane monooxygenase hydroxylase from Methylococcus capsulatus (Bath) demonstrating geometrical variability at the dinuclear iron active site. J Am Chem Soc (2001) 1.49
Site-specific mutagenesis: retrospective and prospective. Carcinogenesis (1991) 1.49
NMR solution structure of a DNA dodecamer duplex containing a cis-diammineplatinum(II) d(GpG) intrastrand cross-link, the major adduct of the anticancer drug cisplatin. Biochemistry (1998) 1.48
Mutagenic and genotoxic effects of three vinyl chloride-induced DNA lesions: 1,N6-ethenoadenine, 3,N4-ethenocytosine, and 4-amino-5-(imidazol-2-yl)imidazole. Biochemistry (1993) 1.47
Gut microbes define liver cancer risk in mice exposed to chemical and viral transgenic hepatocarcinogens. Gut (2010) 1.47
Steroid hormones induce HMG1 overexpression and sensitize breast cancer cells to cisplatin and carboplatin. Proc Natl Acad Sci U S A (2000) 1.46
Possible role for thymine glycol in the selective inhibition of DNA synthesis on oxidized DNA templates. Cancer Res (1985) 1.46
Genetic effects of thymine glycol: site-specific mutagenesis and molecular modeling studies. Proc Natl Acad Sci U S A (1989) 1.44
An ultraviolet light-damaged DNA recognition protein absent in xeroderma pigmentosum group E cells binds selectively to pyrimidine (6-4) pyrimidone photoproducts. Nucleic Acids Res (1992) 1.42
The mismatch-repair protein hMSH2 binds selectively to DNA adducts of the anticancer drug cisplatin. Chem Biol (1996) 1.42
X-ray fiber diffraction evidence for neighbor exclusion binding of a platinum metallointercalation reagent to DNA. Proc Natl Acad Sci U S A (1975) 1.39
Characterization of a DNA damage-recognition protein from mammalian cells that binds specifically to intrastrand d(GpG) and d(ApG) DNA adducts of the anticancer drug cisplatin. Biochemistry (1990) 1.38
New chemistry of an old molecule: cis-[Pt(NH3)2Cl2]. Science (1982) 1.37
Construction and characterization of extrachromosomal probes for mutagenesis by carcinogens: site-specific incorporation of O6-methylguanine into viral and plasmid genomes. Proc Natl Acad Sci U S A (1984) 1.34
Bending studies of DNA site-specifically modified by cisplatin, trans-diamminedichloroplatinum(II) and cis-[Pt(NH3)2(N3-cytosine)Cl]+. Biophys Chem (1990) 1.34
Identification and characterization of a novel linkage isomerization in the reaction of trans-diamminedichloroplatinum(II) with 5'-d(TCTACGCGTTCT). Biochemistry (1990) 1.33
Metallointercalation reagents. 2-hydroxyethanethiolato(2,2',2'-terpyridine)-platinum(II) monocation binds strongly to DNA by intercalation. Proc Natl Acad Sci U S A (1974) 1.33
Antibodies elicited against cis-diamminedichloroplatinum(II)-modified DNA are specific for cis-diamminedichloroplatinum(II)-DNA adducts formed in vivo and in vitro. Proc Natl Acad Sci U S A (1982) 1.33
Replication inhibition and translesion synthesis on templates containing site-specifically placed cis-diamminedichloroplatinum(II) DNA adducts. Biochemistry (1992) 1.33
An intrastrand d(GpG) platinum crosslink in duplex M13 DNA is refractory to repair by human cell extracts. Proc Natl Acad Sci U S A (1992) 1.29
Mutational properties of the primary aflatoxin B1-DNA adduct. Proc Natl Acad Sci U S A (1996) 1.29
Context-dependent mutagenesis by DNA lesions. Chem Biol (1999) 1.28
Effect of 3' flanking neighbors on kinetics of pairing of dCTP or dTTP opposite O6-methylguanine in a defined primed oligonucleotide when Escherichia coli DNA polymerase I is used. Proc Natl Acad Sci U S A (1989) 1.26
Cisplatin-DNA adducts are molecular decoys for the ribosomal RNA transcription factor hUBF (human upstream binding factor). Proc Natl Acad Sci U S A (1994) 1.22
Structure of the soluble methane monooxygenase regulatory protein B. Proc Natl Acad Sci U S A (1999) 1.20
Influence of cisplatin intrastrand crosslinking on the conformation, thermal stability, and energetics of a 20-mer DNA duplex. Proc Natl Acad Sci U S A (1996) 1.20
Isolation of cDNAs encoding a human protein that binds selectively to DNA modified by the anticancer drug cis-diamminedichloroplatinum(II) Proc Natl Acad Sci U S A (1989) 1.19
Multiple pathways of recombination define cellular responses to cisplatin. Chem Biol (2000) 1.18
Inhibition of the BamHI cleavage and unwinding of pBR322 deoxyribonucleic acid by the antitumor drug cis-dichlorodiammineplatinum(II). Biochemistry (1981) 1.17
Excretion of an aflatoxin-guanine adduct in the urine of aflatoxin B1-treated rats. Cancer Res (1981) 1.17
Ethidium bromide changes the nuclease-sensitive DNA binding sites of the antitumor drug cis-diamminedichloroplatinum(II). Proc Natl Acad Sci U S A (1982) 1.16
Component interactions in the soluble methane monooxygenase system from Methylococcus capsulatus (Bath). Biochemistry (1999) 1.16
Xenon and halogenated alkanes track putative substrate binding cavities in the soluble methane monooxygenase hydroxylase. Biochemistry (2001) 1.16
Site-specific mutagenesis by O6-alkylguanines located in the chromosomes of mammalian cells: influence of the mammalian O6-alkylguanine-DNA alkyltransferase. Proc Natl Acad Sci U S A (1989) 1.14
Substrate specificity of ultraviolet DNA endonuclease (UVDE/Uve1p) from Schizosaccharomyces pombe. Nucleic Acids Res (1999) 1.13
Binding of platinum and palladium metallointercalation reagents and antitumor drugs to closed and open DNAs. Biochemistry (1976) 1.13
In vivo effects of cis- and trans-diamminedichloroplatinum(II) on SV40 chromosomes: differential repair, DNA-protein cross-linking, and inhibition of replication. Biochemistry (1985) 1.12
Telomere loss in cells treated with cisplatin. Proc Natl Acad Sci U S A (1998) 1.11
The HMG-domain protein Ixr1 blocks excision repair of cisplatin-DNA adducts in yeast. Mutat Res (1996) 1.11
Interaction of FACT, SSRP1, and the high mobility group (HMG) domain of SSRP1 with DNA damaged by the anticancer drug cisplatin. J Biol Chem (2001) 1.10
Binding of cis- and trans-dichlorodiammineplatinum(II) to the nucleosome core. Proc Natl Acad Sci U S A (1979) 1.10
p53-Dependent and -independent responses to cisplatin in mouse testicular teratocarcinoma cells. Proc Natl Acad Sci U S A (1998) 1.08
Human endonuclease III acts preferentially on DNA damage opposite guanine residues in DNA. Biochemistry (2001) 1.07
Synthesis and characterization of trans-[Pt(NH3)2Cl2] adducts of d(CCTCGAGTCTCC).d(GGAGACTCGAGG). Biochemistry (1990) 1.07
Single d(GpG)/cis-diammineplatinum(II) adduct-induced inhibition of DNA polymerization. Biochemistry (1999) 1.07
Photoreactivity of platinum(II) in cisplatin-modified DNA affords specific cross-links to HMG domain proteins. Biochemistry (1996) 1.06
Effect of the antitumor drug cis-diamminedichloroplatinum(II) and related platinum complexes on eukaryotic DNA replication. Biochemistry (1990) 1.06
Synthesis and biological activity of DNA damaging agents that form decoy binding sites for the estrogen receptor. Proc Natl Acad Sci U S A (1996) 1.05
Binding of [(dien)PtCl] Cl to poly(dG-dC)-poly(dG-dC) facilitates the B goes to Z conformational transition. Nucleic Acids Res (1982) 1.05
Intercalating residues determine the mode of HMG1 domains A and B binding to cisplatin-modified DNA. Biochemistry (2000) 1.05
DNA sequence context and protein composition modulate HMG-domain protein recognition of cisplatin-modified DNA. Biochemistry (1997) 1.04
A single HMG domain in high-mobility group 1 protein binds to DNAs as small as 20 base pairs containing the major cisplatin adduct. Biochemistry (1995) 1.04